Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Diabetes

Free Subscription Articles published in Kidney Int Retrieve available abstracts of 88 articles: HTML format

Single Articles

December 2024
1. MIMURA I, Chen Z, Natarajan R
   Epigenetic alterations and memory: key players in the development/progression of chronic kidney disease promoted by acute kidney injury and diabetes.
   Kidney Int. 2024 Dec 24:S0085-2538(24)00918-9. doi: 10.1016/j.kint.2024.
   PubMed     Abstract available
   
   
   
2. FOLESTAD E, Mehlem A, Ning FC, Oosterveld T, et al
   Vascular endothelial growth factor B-mediated fatty acid flux in the adipose-kidney axis contributes to lipotoxicity in diabetic kidney disease.
   Kidney Int. 2024 Dec 15:S0085-2538(24)00872-X. doi: 10.1016/j.kint.2024.
   PubMed     Abstract available
   
   
   
3. KRISHNAN S, Manoharan J, Wang H, Gupta D, et al
   Corrigendum to "CD248 induces a maladaptive unfolded protein response in diabetic kidney disease." Kidney International 2023;103:304-319.
   Kidney Int. 2024;106:1193-1196.
   PubMed    
   
   
   November 2024
4. LV Z, Hu J, Su H, Yu Q, et al
   TRAIL induces podocyte PANoptosis via death receptor 5 in diabetic kidney disease.
   Kidney Int. 2024 Nov 19:S0085-2538(24)00800-7. doi: 10.1016/j.kint.2024.
   PubMed     Abstract available
   
   
   
5. MIYAMOTO S, Heerspink HJL, de Zeeuw D, Sakamoto K, et al
   A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope.
   Kidney Int. 2024;106:972-984.
   PubMed     Abstract available
   
   
   September 2024
6. NARONGKIATIKHUN P, Bjornstad P
   Deciphering the kidney hemodynamic effects of SGLT2 inhibition: translating insights from rats to humans in type 2 diabetes.
   Kidney Int. 2024;106:354-356.
   PubMed     Abstract available
   
   
   
7. VIVARELLI M, Barratt J, Beck LH Jr, Fakhouri F, et al
   The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
   Kidney Int. 2024;106:369-391.
   PubMed     Abstract available
   
   
   August 2024
8. SELVARAJAH V, Robertson D, Hansen L, Jermutus L, et al
   A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease.
   Kidney Int. 2024 Aug 30:S0085-2538(24)00629-X. doi: 10.1016/j.kint.2024.
   PubMed     Abstract available
   
   
   July 2024
9. HEROLD JM, Wiegrebe S, Nano J, Jung B, et al
   Population-based reference values for kidney function and kidney function decline in 25- to 95-year-old Germans without and with diabetes.
   Kidney Int. 2024 Jul 29:S0085-2538(24)00528-3. doi: 10.1016/j.kint.2024.
   PubMed     Abstract available
   
   
   
10. DRUEKE TB, Massy ZA
    Unexpected metabolic effects of sodium-glucose cotransporter 2 inhibitors.
    Kidney Int. 2024;106:12-15.
    PubMed    
    
    
    
11. FENG Y, Sun Z, Fu J, Zhong F, et al
    Podocyte-derived soluble RARRES1 drives kidney disease progression through direct podocyte and proximal tubular injury.
    Kidney Int. 2024;106:50-66.
    PubMed     Abstract available
    
    
    June 2024
12. NANGAKU M
    SGLT2 inhibitor: 2-way superstar in nephrology?
    Kidney Int. 2024;105:1176-1177.
    PubMed    
    
    
    
13. KUME S, Packer M
    SGLT2 inhibitors act as metabolic transducers to restore healthy nutrient deprivation and surplus signaling in the kidney.
    Kidney Int. 2024;105:1172-1176.
    PubMed    
    
    
    
14. YAU K, Cherney DZI, van Raalte DH, Wever BE, et al
    Kidney protective mechanisms of SGLT2 inhibitors: evidence for a hemodynamic effect.
    Kidney Int. 2024;105:1168-1172.
    PubMed    
    
    
    
15. MCEVOY CM, Yuen DA
    Not too much, not too little-just the right amount: the story of YAP in the podocyte.
    Kidney Int. 2024;105:1157-1159.
    PubMed     Abstract available
    
    
    May 2024
16. WADA Y, Kidokoro K, Kondo M, Tokuyama A, et al
    Evaluation of glomerular hemodynamic changes by sodium-glucose-transporter 2 inhibition in type 2 diabetic rats using in vivo imaging.
    Kidney Int. 2024 May 25:S0085-2538(24)00340-5. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
17. HONG YA, Nangaku M
    Endogenous adenine as a key player in diabetic kidney disease progression: an integrated multiomics approach.
    Kidney Int. 2024;105:918-920.
    PubMed    
    
    
    
18. WANG L, Tian H, Wang H, Mao X, et al
    Disrupting circadian control of autophagy induces podocyte injury and proteinuria.
    Kidney Int. 2024;105:1020-1034.
    PubMed     Abstract available
    
    
    April 2024
19. MURPHY DP, Wolfson J, Reule S, Johansen KL, et al
    A cohort study of sodium-glucose cotransporter-2 inhibitors after acute kidney injury among Veterans with diabetic kidney disease.
    Kidney Int. 2024 Apr 27:S0085-2538(24)00309-0. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    March 2024
20. NEGRI AL
    Sodium-glucose cotransporter 2 inhibitors in the treatment of refractory hypomagnesemia.
    Kidney Int. 2024;105:638.
    PubMed    
    
    
    
21. SHAH CV
    Sodium-glucose cotransporter 2 inhibition, epidermal growth factor, and magnesium homeostasis: is there a link?
    Kidney Int. 2024;105:638-639.
    PubMed    
    
    
    
22. CHEN JJ, Lee TH, Yang HY
    Exploring nontraditional cardiorenal advantages of SGLT-2 inhibitors and GLP-1 receptor agonists.
    Kidney Int. 2024;105:442-444.
    PubMed     Abstract available
    
    
    February 2024
23. CHEN J, Wang X, He Q, Yang HC, et al
    Inhibition of transcriptional coactivator YAP Impairs the expression and function of transcription factor WT1 in diabetic podocyte injury.
    Kidney Int. 2024 Feb 27:S0085-2538(24)00160-1. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    January 2024
24. MUTO Y, Humphreys BD
    Leveraging multimodal chromatin profiling to identify a new potential driver of diabetic kidney disease.
    Kidney Int. 2024;105:25-27.
    PubMed     Abstract available
    
    
    December 2023
25. FU EL, Mastrorilli J, Bykov K, Wexler DJ, et al
    A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.
    Kidney Int. 2023 Dec 13:S0085-2538(23)00865-7. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    
26. SOURRIS KC, Ding Y, Maxwell SS, Al-Sharea A, et al
    Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation.
    Kidney Int. 2023 Dec 5:S0085-2538(23)00756-1. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    
27. LIZOTTE F, Rousseau M, Denhez B, Levesque D, et al
    Erratum to "Deletion of protein tyrosine phosphatase SHP-1 restores SUMOylation of podocin and reverses the progression of diabetic kidney disease." Kidney Int. 2023;104:787-802.
    Kidney Int. 2023;104:1228.
    PubMed    
    
    
    
28. IWAGAMI M
    Post hoc analysis of the SONAR trial: potential analgesic effects of atrasentan?
    Kidney Int. 2023;104:1062-1064.
    PubMed     Abstract available
    
    
    November 2023
29. EUN M, Kim D, Shin SI, Yang HO, et al
    Chromatin accessibility analysis and architectural profiling of human kidneys reveal key cell types and a regulator of diabetic kidney disease.
    Kidney Int. 2023 Nov 2:S0085-2538(23)00757-3. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    
30. FANG Z, Lee K, He JC
    A central role for mesangial cells in the initiation of diabetic nephropathy.
    Kidney Int. 2023;104:872-874.
    PubMed    
    
    
    October 2023
31. AZUSHIMA K, Kovalik JP, Yamaji T, Ching J, et al
    Abnormal lactate metabolism is linked to albuminuria and kidney injury in diabetic nephropathy.
    Kidney Int. 2023 Oct 5:S0085-2538(23)00565-3. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    September 2023
32. SMERKOUS D, Mauer M, Tondel C, Svarstad E, et al
    Development of an automated estimation of foot process width using deep learning in kidney biopsies from patients with Fabry, minimal change, and diabetic kidney diseases.
    Kidney Int. 2023 Sep 27:S0085-2538(23)00675-0. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    August 2023
33. CHAN KW, Smeijer JD, Schechter M, Jongs N, et al
    Post-hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease.
    Kidney Int. 2023 Aug 30:S0085-2538(23)00610-5. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    
34. SEN T, Ju W, Nair V, Ladd P, et al
    Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes.
    Kidney Int. 2023 Aug 3:S0085-2538(23)00537-9. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    July 2023
35. LIZOTTE F, Rousseau M, Denhez B, Levesque D, et al
    Deletion of protein tyrosine phosphatase SHP-1 restores SUMOylation of podocin and reverses the progression of diabetic kidney disease.
    Kidney Int. 2023 Jul 26:S0085-2538(23)00502-1. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    
36. HONG S, Kim KS, Han K, Park CY, et al
    A cohort study found a high risk of end-stage kidney disease associated with acromegaly.
    Kidney Int. 2023 Jul 23:S0085-2538(23)00501-X. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    
37. MIMURA I, Nangaku M
    Epigenetic regulation of angiogenesis and ischemic response by long noncoding RNA LEENE in diabetes.
    Kidney Int. 2023 Jul 5:S0085-2538(23)00483-0. doi: 10.1016/j.kint.2023.
    PubMed    
    
    
    
38. HEERSPINK HJL, Jongs N, Neuen BL, Schloemer P, et al
    Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials.
    Kidney Int. 2023;104:181-188.
    PubMed     Abstract available
    
    
    April 2023
39. CHAPMAN D, Judge PK, Sardell RJ, Staplin N, et al
    Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors.
    Kidney Int. 2023;103:787-790.
    PubMed    
    
    
    
40. CHEN Z, Zhu Z, Liang W, Luo Z, et al
    Reduction of anaerobic glycolysis contributes to angiotensin II-induced podocyte injury with foot process effacement.
    Kidney Int. 2023;103:735-748.
    PubMed     Abstract available
    
    
    February 2023
41. TUTTLE KR, Bosch-Traberg H, Cherney DZI, Hadjadj S, et al
    Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared to placebo.
    Kidney Int. 2023 Feb 2:S0085-2538(23)00056-X. doi: 10.1016/j.kint.2022.
    PubMed     Abstract available
    
    
    
42. CAZA TN, Larsen CP
    False-positive anti-PLA2R ELISA testing in patients with diabetes mellitus.
    Kidney Int. 2023;103:425.
    PubMed    
    
    
    January 2023
43. FU EL, Kutz A, Desai RJ
    Finerenone in chronic kidney disease and type 2 diabetes: the known and the unknown.
    Kidney Int. 2023;103:30-33.
    PubMed     Abstract available
    
    
    December 2022
44. RAYEGO-MATEOS S, Rodrigues-Diez R, Fernandez-Fernandez B, Mora-Fernandez C, et al
    Targeting inflammation to treat diabetic kidney disease: the road to 2030.
    Kidney Int. 2022 Dec 2:S0085-2538(22)01017-1. doi: 10.1016/j.kint.2022.
    PubMed     Abstract available
    
    
    
45. WU H, Humphreys BD
    Immune cell heterogeneity in a mouse model of diabetic kidney disease.
    Kidney Int. 2022;102:1215-1216.
    PubMed     Abstract available
    
    
    November 2022
46. 
    KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.
    Kidney Int. 2022;102.
    PubMed    
    
    
    
47. ROSSING P, Caramori ML, Chan JCN, Heerspink HJL, et al
    Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence.
    Kidney Int. 2022;102:990-999.
    PubMed     Abstract available
    
    
    October 2022
48. BAKRIS GL, Ruilope LM, Anker SD, Filippatos G, et al
    Analysis from the FIDELITY study examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes.
    Kidney Int. 2022 Oct 28. pii: S0085-2538(22)00910.
    PubMed     Abstract available
    
    
    
49. KRISHNAN S, Manoharan J, Wang H, Gupta D, et al
    CD248 induces a maladaptive unfolded protein response in diabetic kidney disease.
    Kidney Int. 2022 Oct 26. pii: S0085-2538(22)00904.
    PubMed     Abstract available
    
    
    
50. LASSEN E, Bouchareb R, Daehn IS
    Podocyte as the link between sterile inflammation and diabetic kidney disease.
    Kidney Int. 2022;102:688-690.
    PubMed     Abstract available
    
    
    September 2022
51. DE BOER IH, Khunti K, Sadusky T, Tuttle KR, et al
    Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).
    Kidney Int. 2022 Sep 27. pii: S0085-2538(22)00634.
    PubMed     Abstract available
    
    
    
52. FU J, Sun Z, Wang X, Zhang T, et al
    The single-cell landscape of kidney immune cells reveals transcriptional heterogeneity in early diabetic kidney disease.
    Kidney Int. 2022 Sep 12. pii: S0085-2538(22)00715.
    PubMed     Abstract available
    
    
    
53. SPEER T, Schunk SJ
    Klotho in diabetic kidney disease: more than dust in the Wnt.
    Kidney Int. 2022;102:469-471.
    PubMed     Abstract available
    
    
    
54. ZHAN P, Zhang Y, Shi W, Liu X, et al
    Myeloid-derived growth factor deficiency exacerbates mitotic catastrophe of podocytes in glomerular disease.
    Kidney Int. 2022;102:546-559.
    PubMed     Abstract available
    
    
    August 2022
55. STEFANSSON VTN, Nair V, Melsom T, Looker HC, et al
    Molecular Programs Associated with Glomerular Hyperfiltration in Early Diabetic Kidney Disease.
    Kidney Int. 2022 Aug 30. pii: S0085-2538(22)00689.
    PubMed     Abstract available
    
    
    
56. XIA Y, Coates PT, Nangaku M
    How does diabetes cause susceptibility to COVID in the kidney: new clues provided by organoids.
    Kidney Int. 2022 Aug 10. pii: S0085-2538(22)00608.
    PubMed    
    
    
    
57. SUZUKI Y, Kaneko H, Okada A, Matsuoka S, et al
    Kidney outcomes in patients with diabetes mellitus did not differ between individual sodium-glucose cotransporter-2 inhibitors.
    Kidney Int. 2022 Aug 4. pii: S0085-2538(22)00510.
    PubMed     Abstract available
    
    
    
58. ZHANG J, Cai J, Cui Y, Jiang S, et al
    Corrigendum to Zhang J, Cai J, Cui Y, Jiang S, Wei J, Kim YC, Chan J, Thalakola A, Le T, Xu L, Wang L, Jiang K, Wang X, Wang H, Cheng F, Buggs J, Koepsell H, Vallon V, Liu R. "Role of the macula densa sodium glucose cotransporter type 1-neuronal nitri
    Kidney Int. 2022;102:448.
    PubMed    
    
    
    
59. RHEE EP
    Proteomic discovery in diabetic kidney disease-to what end?
    Kidney Int. 2022;102:236-238.
    PubMed     Abstract available
    
    
    July 2022
60. ZENG W, Beyene HB, Kuokkanen M, Miao G, et al
    Lipidomic profiling in the Strong Heart Study identified American Indians at risk of chronic kidney disease.
    Kidney Int. 2022 Jul 16. pii: S0085-2538(22)00536.
    PubMed     Abstract available
    
    
    
61. JAGANNATHAN G, Finkielstein VA, Markowitz GS, Kudose S, et al
    Armanni-Ebstein lesion in a diabetic patient with acute tubular injury.
    Kidney Int. 2022;102:213.
    PubMed    
    
    
    June 2022
62. SHAHZAD K, Fatima S, Khawaja H, Elwakiel A, et al
    Podocyte-specific Nlrp3 inflammasome activation promotes diabetic kidney disease.
    Kidney Int. 2022 Jun 29. pii: S0085-2538(22)00513.
    PubMed     Abstract available
    
    
    
63. TUTTLE KR, Agarwal R, Alpers CE, Bakris GL, et al
    Molecular Mechanisms and Therapeutic Targets for Diabetic Kidney Disease.
    Kidney Int. 2022 Jun 2. pii: S0085-2538(22)00436.
    PubMed     Abstract available
    
    
    
64. 
    Corrigendum to Fang Y, Chen B, Gong AY, et al. "The ketone body beta-hydroxybutyrate mitigates the senescence response of glomerular podocytes to diabetic insults." Kidney Int. 2021;100:1037-1053.
    Kidney Int. 2022;101:1301-1302.
    PubMed    
    
    
    May 2022
65. CHEN X, Tan H, Xu J, Tian Y, et al
    Klotho-derived peptide 6 ameliorates diabetic kidney disease by targeting Wnt/beta-catenin signaling.
    Kidney Int. 2022 May 26. pii: S0085-2538(22)00378.
    PubMed     Abstract available
    
    
    
66. MONTAGUD-MARRAHI E, Cuadrado-Payan E, Hermida E, Cacho J, et al
    Preemptive simultaneous pancreas kidney transplantation has survival benefit to patient.
    Kidney Int. 2022 May 26. pii: S0085-2538(22)00385.
    PubMed     Abstract available
    
    
    
67. KOBAYASHI H, Looker HC, Satake E, Saulnier PJ, et al
    Results of untargeted analysis using the SOMAscan proteomics platform indicates novel associations of circulating proteins with risk of progression to kidney failure in diabetes.
    Kidney Int. 2022 May 23. pii: S0085-2538(22)00372.
    PubMed     Abstract available
    
    
    
68. LI H, Zhao X, Zheng L, Wang X, et al
    Bruceine A protects against diabetic kidney disease via inhibiting galectin-1.
    Kidney Int. 2022 May 19. pii: S0085-2538(22)00369.
    PubMed     Abstract available
    
    
    
69. NAGAI Y, Matoba K, Takeda Y, Yako H, et al
    Rho-associated, coiled-coil-containing protein kinase 1 regulates development of diabetic kidney disease via modulation of fatty acid metabolism.
    Kidney Int. 2022 May 18. pii: S0085-2538(22)00370.
    PubMed     Abstract available
    
    
    
70. PRUIJM M, Phan O, Zanchi A
    Metformin versus SGLT-2 inhibitors: how low can we go?
    Kidney Int. 2022;101:874-877.
    PubMed     Abstract available
    
    
    
71. NISHI H
    Lay A TRAP for myeloid cell response in diabetic kidney disease.
    Kidney Int. 2022;101:872-874.
    PubMed     Abstract available
    
    
    April 2022
72. XIE Y, E J, Cai H, Zhong F, et al
    Reticulon-1A mediates diabetic kidney disease progression through endoplasmic reticulum-mitochondrial contacts in tubular epithelial cells.
    Kidney Int. 2022 Apr 22. pii: S0085-2538(22)00336.
    PubMed     Abstract available
    
    
    March 2022
73. CORREMANS R, Neven E, Maudsley S, Leysen H, et al
    Progression of established non-diabetic chronic kidney disease is halted by metformin treatment in rats.
    Kidney Int. 2022 Mar 7. pii: S0085-2538(22)00176.
    PubMed     Abstract available
    
    
    
74. PRESSLY JD, Ge M, Fornoni A
    LPCing through the nephron accelerates diabetic kidney disease.
    Kidney Int. 2022;101:454-456.
    PubMed     Abstract available
    
    
    February 2022
75. HARUHARA K, Suzuki T, Wakui H, Azushima K, et al
    Deficiency of the kidney tubular angiotensin II type1 receptor-associated protein ATRAP exacerbates streptozotocin-induced diabetic glomerular injury via reducing protective macrophage polarization.
    Kidney Int. 2022 Feb 28. pii: S0085-2538(22)00161.
    PubMed     Abstract available
    
    
    
76. SASAKO T, Yamauchi T
    Addressing screams for evidence on renoprotection by GLP-1 receptor agonists.
    Kidney Int. 2022;101:222-224.
    PubMed     Abstract available
    
    
    
77. XU Y, Fu EL, Clase CM, Mazhar F, et al
    GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes.
    Kidney Int. 2022;101:360-368.
    PubMed     Abstract available
    
    
    
78. HONG Q, Cai H, Zhang L, Li Z, et al
    Modulation of transforming growth factor-beta-induced kidney fibrosis by leucine-rich -2 glycoprotein-1.
    Kidney Int. 2022;101:299-314.
    PubMed     Abstract available
    
    
    January 2022
79. HASEGAWA S, Nangaku M
    SGLT2 inhibition in chronic kidney disease: a preventive strategy against acute kidney injury at the same time?
    Kidney Int. 2022;101:20-22.
    PubMed     Abstract available
    
    
    December 2021
80. 
    Corrigendum to Mann JFE, Muskiet MHA. Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists. Kidney Int. 2021;99:314-318.
    Kidney Int. 2021;100:1351-1352.
    PubMed    
    
    
    
81. 
    Corrigendum to Wu L, Liu C, Chang D-Y, et al. Annexin A1 alleviates kidney injury by promoting the resolution of inflammation in diabetic nephropathy. Kidney Int. 2021;100:107-121.
    Kidney Int. 2021;100:1349-1350.
    PubMed    
    
    
    November 2021
82. YOSHIOKA K, Hirakawa Y, Kurano M, Ube Y, et al
    Lysophosphatidylcholine mediates fast decline in kidney function in diabetic kidney disease.
    Kidney Int. 2021 Nov 29. pii: S0085-2538(21)01084.
    PubMed     Abstract available
    
    
    
83. ZHANG J, Cai J, Cui Y, Jiang S, et al
    Role of the macula densa sodium glucose cotransporter type 1-nitric oxide synthase 1-tubuloglomerular feedback pathway in diabetic hyperfiltration.
    Kidney Int. 2021 Nov 26. pii: S0085-2538(21)01078.
    PubMed     Abstract available
    
    
    
84. ANSERMET C, Centeno G, Bignon Y, Ortiz D, et al
    Dysfunction of the circadian clock in the kidney tubule leads to enhanced kidney gluconeogenesis and exacerbated hyperglycemia in diabetes.
    Kidney Int. 2021 Nov 24. pii: S0085-2538(21)01081.
    PubMed     Abstract available
    
    
    
85. KAESLER N, Schreibing F, Speer T, Puente-Secades S, et al
    Altered vitamin K biodistribution and metabolism in experimental and human chronic kidney disease.
    Kidney Int. 2021 Nov 10. pii: S0085-2538(21)01056.
    PubMed     Abstract available
    
    
    
86. KUME S
    Ketone bodies: back to a place in the sun.
    Kidney Int. 2021;100:976-978.
    PubMed     Abstract available
    
    
    October 2021
87. MOLLER-HACKBARTH K, Dabaghie D, Charrin E, Zambrano S, et al
    Retinoic acid receptor responder1 promotes development of glomerular diseases via the Nuclear Factor-kappaB signaling pathway.
    Kidney Int. 2021;100:809-823.
    PubMed     Abstract available
    
    
    September 2021
88. HEERSPINK HJ, Cherney D, Postmus D, Stefansson BV, et al
    A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.
    Kidney Int. 2021 Sep 21. pii: S0085-2538(21)00865.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge.